ResMed, Nyxoah Team Up to Grow Sleep Apnea Awareness & Therapy in Germany

ResMed Germany began a partnership with Nyxoah, a company developing solutions to treat obstructive sleep apnea (OSA), in order to grow OSA awareness and therapy use in the German market.
 
Nyxoah produces the Genio system, a leadless, battery-free hypoglossal neurostimulation therapy for OSA. Genio currently holds a CE mark and the company is now conducting the DREAM IDE pivotal study for U.S. Food and Drug Administration (FDA) approval.
 
The duo said they will create a full continuum of care to educate and guide OSA patients in Germany from diagnosis through treatment. They said they’ll work to speed patient identification and more aptly support patient setups on appropriate therapy, as well.
 
The collaboration will entail both companies providing OSA helplines and direct-to-consumer initiatives, sales/marketing efforts to target ENTs and sleep physicians, and patient/clinician educational education programs and symposiums.
 
“We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration,” Nyxoah’s CEO Olivier Taelman told the press. “The OSA ecosystem created by this partnership will guide patients from diagnosis to the right treatment for them, whether that is a mandibular device, continuous positive airway pressure (CPAP), or hypoglossal nerve stimulation (HGNS).”
 
“It is our joint goal to enable more patients to receive effective, personalized therapy,” added ResMed Germany president Katrin Pucknat. “Over 95 percent of patients in Germany suffering from sleep apnea are not diagnosed or treated. In addition, there are patients who have problems with their therapy and just stop it without considering an alternative. The partnership with Nyxoah will enable us to broaden the education around therapy options and empower patients to benefit from improved health outcomes.”